文献速递膀胱癌与上尿路尿路上皮癌

iRECIST与RECIST评估帕博利珠单抗治疗转移性尿路上皮癌疗效的比较

Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab.
PubMed 文献 · BJU Int · 2020-08-06

该多中心回顾性研究纳入91例接受二线帕博利珠单抗治疗的转移性尿路上皮癌患者,比较iRECIST与RECIST 1.1的疗效评估价值。结果显示iRECIST较RECIST能更准确预测总生存,并具有更好的净获益。

要点

  • 57例RECIST进展患者中,iRECIST重新分类为免疫稳定疾病6例(10.5%)、免疫部分缓解2例(3.5%)、免疫完全缓解2例(3.5%)。
  • iRECIST的客观缓解(HR 0.10,95%CI 0.03-0.35;P=0.001)和进展时间(HR 0.59,95%CI 0.46-0.77;P<0.001)均与全因死亡显著相关。
  • iRECIST对总生存的预测能力优于RECIST(客观缓解c-index 0.70,提高0.04,P=0.046;进展时间c-index 0.88,提高0.07,P=0.039)。

核心结论

  • 与RECIST相比,iRECIST能更准确预测接受帕博利珠单抗治疗的转移性尿路上皮癌患者的总生存。
  • iRECIST有潜力成为该类患者肿瘤疗效评估的新标准。

研究设计与样本

  • 多中心回顾性研究,纳入91例接受二线帕博利珠单抗治疗的转移性尿路上皮癌患者。
  • 比较iRECIST与RECIST 1.1的客观缓解和进展时间与总生存及全因死亡风险的关系,采用log-rank检验和多变量Cox回归分析。
  • 采用Harrell一致性指数(c-index)评估预测性能,并采用决策曲线分析比较临床实用性。

主要发现

  • 57例按RECIST判定为进展的患者中,按iRECIST重新分类为免疫稳定疾病6例(10.5%)、免疫部分缓解2例(3.5%)、免疫完全缓解2例(3.5%)。
  • 多变量Cox回归显示,iRECIST的客观缓解(HR 0.10,95%CI 0.03-0.35;P=0.001)和进展时间(HR 0.59,95%CI 0.46-0.77;P<0.001)均与全因死亡显著相关。
  • iRECIST对总生存的预测能力显著优于RECIST(客观缓解c-index 0.70,提高0.04,P=0.046;进展时间c-index 0.88,提高0.07,P=0.039)。
  • 决策曲线分析显示iRECIST较RECIST具有更好的净获益。

临床怎么用

  • 在接受帕博利珠单抗治疗的转移性尿路上皮癌患者中,可考虑采用iRECIST评估疗效以更准确预测总生存。
  • 对于RECIST判定为进展的患者,iRECIST可能识别出部分仍可从免疫治疗中获益的免疫稳定疾病或缓解患者。

局限性

  • 本研究为回顾性研究,样本量91例,可能存在选择偏倚。
  • iRECIST作为新标准的潜力仍需前瞻性研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the clinical usefulness of Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) in patients with metastatic urothelial carcinoma (UC) treated with pembrolizumab. The iRECIST is designed to accurately capture the tumour response treated with immunotherapy. PATIENTS AND METHODS: We conducted a multicentre retrospective study evaluating the clinical utility of iRECIST in 91 patients with metastatic UC treated with second-line pembrolizumab. The objective response (OR) and time to progression (TTP) in accordance with both iRECIST and RECIST version 1.1 were compared with overall survival (OS) and risk of all-cause mortality, and analysed using log-rank and multivariable Cox regression models, respectively. Predictive performance of the criteria was studied using Harrell's concordance index (c-index). The clinical usefulness of each criterion was compared using decision curve analysis. RESULTS: Of 57 patients with progressive disease per RECIST, a considerable number of patients were reclassified to immune stable disease (six, 10.5%), immune partial response (two, 3.5%), and immune complete response (two, 3.5%) per iRECIST. Multivariable Cox regression models showed that both OR (hazard ratio [HR] 0.10, 95% confidence interval [CI] 0.03-0.35; P = 0.001) and TTP (HR 0.59, 95% CI 0.46-0.77; P < 0.001) per iRECIST were significantly associated with all-cause mortality. Furthermore, iRECIST had a significant, increased predictability of OS compared with RECIST (OR, c-index: 0.70, increase: 0.04, P = 0.046; TTP, c-index: 0.88, increase: 0.07, P = 0.039). On decision curve analysis, iRECIST presented better net benefit gains than did RECIST. CONCLUSIONS: Compared with RECIST, iRECIST could more accurately predict OS of patients with metastatic UC treated with pembrolizumab. The iRECIST has the potential to be a new standard for tumour response evaluation of these patients.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Fukuokaya W, Kimura T, Yanagisawa T, et al. Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab. BJU Int. 2020. PMID: 32662189. doi:10.1111/bju.15176

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。